Aurora Financial JournalInDex Pharmaceuticals Holding AB (FLERIE.ST)
Nasdaq Stockholm · Financial statements, TTM figures and earnings dates
In fiscal year 2024 (ended December 31, 2024), InDex Pharmaceuticals Holding AB reported revenue of SEK 100.0K and net income of −SEK 228.0M. Annual financial statements are available for fiscal years 2023 to 2024, taken from the company's ESEF annual reports (IFRS).
Open interactive financials →Key financials
| SEK | FY2024 2024-12-31 | FY2023 2023-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | SEK 100.0K | SEK 0 |
| Operating income | −SEK 275.0M | −SEK 571.1M |
| Net income | −SEK 228.0M | −SEK 559.6M |
| Diluted EPS | −SEK 3.24 | −SEK 11.34 |
| Cash flow | ||
| Operating cash flow | −SEK 17.0M | −SEK 73.8M |
| Balance sheet | ||
| Cash and equivalents | SEK 865.1M | SEK 330.0M |
| Total assets | SEK 4.22B | SEK 3.58B |
| Total liabilities | SEK 25.3M | SEK 17.6M |
| Shareholders' equity | SEK 4.20B | SEK 3.57B |
TTM = trailing twelve months (balance-sheet items at the latest quarter end). Figures in SEK as reported; per-share data adjusted for stock splits.
Annual reports
More on the interactive page
The full FLERIE.ST page on Aurora Financial Journal includes every fiscal year since the company began filing structured data, income statement, balance sheet and cash flow statement line by line, charts for every measure, valuation multiples (P/E, P/S, P/B), live price charts and the earnings calendar.
Open FLERIE.ST financials →